01.11.2017 • NewsElaine BurridgeEvonikH2O2

Evonik Reshapes H2O2 Business

(c) Evonik
(c) Evonik

Evonik is reshaping its hydrogen peroxide (H2O2) portfolio to become more customer-focused and in response to growing demand for its Hyprox, Oxteril, Persynt and Clarmarin brands. The German group said it is currently working on an extensive program to realign its four production sites in Europe, located at Delfzijl, the Netherlands; Antwerp, Belgium; Rheinfelden, Germany and Weissenstein, Switzerland.

The program will see capacity expanded and commissioned this year as well as the establishment of a new logistics center, which Evonik said would enable the business to offer smaller package sizes. Details on actual production figures and the location of the logistics center were not disclosed.

Susanne Reinhart, head of the company’s Active Oxygens Europe, Middle East & Africa business area, said that following the realignment Evonik will be faster, more flexible and closer to its customers in various industries, including pharmaceutical and cosmetics, processing of food packaging, pulp and textiles. “We want to be able to react to the very different requirements of our customers and to work together with them to develop solution concepts for the future,” she said.

Evonik, which produces around 950,000 t/y of the bleaching agent and claims to be the second largest producer worldwide, expects to finish implementing the measures resulting from its realignment program by the middle of 2018.

In separate news, the Korea Herald newspaper reported that Evonik is in talks with South Korea’s SK Chemicals (SKC) to collaborate on H2O2 as well as on hydrogen peroxide-to-propylene oxide (HPPO) technology. SKC said a partnership in HPPO technology could help both companies secure a bigger presence in the PO market.

Interview

Fostering Innovation and Collaboration
Specialty Chemicals Distributor IMCD’s Strategy

Fostering Innovation and Collaboration

Valerie Diele-Braun, CEO of IMCD, shares her vision for sustainability, global expansions, and strategic direction in an exclusive CHEManager International interview.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
19.03.2025 • NewsInnovation

Data-Driven Enzyme Immobilization

Inseit, based in Bern, develops biocatalysts for industrial setups using enzyme immobilization and biocomputation. Addressing biotech and sustainability challenges, Inseit was selected for Venture Leaders Biotech and won two Nucleate accelerator prizes.

Photo
27.03.2025 • News

J&J to Invest $55 Billion in US Operations

US healthcare giant Johnson & Johnson (J&J) has unveiled plans to invest over $55 billion in the US over the next four years. This significant investment marks a 25% increase compared to the previous four years, the company said.

Photo
24.01.2025 • News

And the Winners are: Cynio, EnaDyne and Green Li-ion

The CHEManager Innovation Pitch, the start-up promotion initiative of CHEManager and CHEManager International, has given more than 100 start-ups from over 15 countries the opportunity to present their innovative ideas, products and technologies to a broad target group since its launch in 2019.